Double placebo design in a prevention trial for Alzheimer's disease
Double placebo design in a prevention trial for Alzheimer's disease
复制标题
DOI：
10.1016/s0197-2456(01)00189-1
复制
发表时间：
2002-02-01
期刊：
影响因子：
--
通讯作者：
Breitner, JCS
中科院分区：
文献类型：
--
作者：
Martin, BK;Meinert, CL;Breitner, JCS
阿尔茨海默病抗炎预防试验（ADAPT）旨在比较两种非甾体抗炎药与安慰剂。两种活性治疗的安慰剂对照可以通过多种方式实现，每种方式对药物供应、入组、治疗依从性和特定治疗比较的有效性的物流可能具有不同的影响。作者概述了ADAPT中考虑的安慰剂设计，讨论了其优缺点，并提供了选择双重安慰剂设计的理由和后果。(C)2002年爱思唯尔科技有限公司All rights reserved.
The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design. (C) 2002 Elsevier Science Inc. All rights reserved.